AC Immune SA Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.5M-85.1% YoYTTM through 31 Dec 2025
Net Income -$88.8MTTM through 31 Dec 2025
Free Cash Flow -$88.6MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -1,940.1% |
| Net Margin | -1,971.7% |
Returns
-157.0%ROE
-45.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.98x
Net Debt-$91.4Mnet cash position
Cash & Equivalents$26.8M
Quality Metrics
Piotroski F-Score1 / 9
FCF Margin-1,968.4%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $3.6M
Diluted EPSFY2025: $-0.70
Dividend
No dividend
Capital Allocation
Capex Intensity20.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Contract Revenue | $3.6M | -86.9% | View detailsExpected partner payments in 2026 include $12 million from Takeda and CHF 10 million from Lilly. |
Financials converted at 0.7917 from CHF.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.